Overview

NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer

Status:
RECRUITING

Trial end date:
2029-09-01

Target enrollment:

Participant gender:

Summary

To explore the safety and efficacy of NALIRIFOX plus targeted therapy versus FOLFOX plus targeted therapy as first-line treatment for metastatic colorectal cancer.

Phase:

PHASE3

Details

Lead Sponsor:

Shanghai Zhongshan Hospital

Treatments:

Folfox protocol